Turnstone Biologics Corp
TSBX0.351USD
+0.001+0.29%
Market hours （ET）Quotes delayed by 15 min
8.12MMarket Cap
LossP/E TTM
More Details of Turnstone Biologics Corp Company
Turnstone Biologics Corp. is a clinical-stage biotechnology company. The Company is focused on developing new medicines to treat and cure patients with solid tumors. It is developing tumor infiltrating lymphocytes (TIL) therapies for the potential treatment of multiple solid tumors. It is also actively advancing its preclinical pipeline programs including TIDAL-02, its next Selected TIL program, and its TIDAL-01 and viral immunotherapy combination program. It is advancing TIDAL-01, its lead Selected TIL product candidate, for the treatment of multiple solid tumor indications. TIDAL-01 utilizes an unbiased identification and functional screening process to isolate and selectively expand the greatest breadth of tumor-reactive TILs from the patient’s tumor. Its next Selected TIL program, TIDAL-02, is being designed to encompass a next generation streamlined manufacturing process for tumor-reactive T cells and additional modifications to enhance TIL quality and function.
Company Info
Ticker SymbolTSBX
Company nameTurnstone Biologics Corp
IPO dateJul 21, 2023
CEODr. Sammy J. Farah, Ph.D.
Number of employees14
Security typeOrdinary Share
Fiscal year-endJul 21
Address9310 Athena Circle, Suite 300
CityLA JOLLA
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code92037
Phone13478975988
Websitehttps://www.turnstonebio.com
Ticker SymbolTSBX
IPO dateJul 21, 2023
CEODr. Sammy J. Farah, Ph.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Ms. Saryah Azmat
Ms. Saryah Azmat
Chief Operating Officer, Corporate Secretary
Chief Operating Officer, Corporate Secretary
--
--
Dr. Sammy J. Farah, Ph.D.
Dr. Sammy J. Farah, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. William D. Waddill
Mr. William D. Waddill
Independent Director
Independent Director
--
--
Dr. Jerel Davis, Ph.D.
Dr. Jerel Davis, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Michael F. (Mike) Burgess, Ph.D.
Dr. Michael F. (Mike) Burgess, Ph.D.
Director
Director
--
--
Mr. Rishi Gupta, J.D.
Mr. Rishi Gupta, J.D.
Independent Director
Independent Director
--
--
Dr. Kanya Rajangam, M.D., Ph.D.
Dr. Kanya Rajangam, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Robert J. Gould, Ph.D.
Dr. Robert J. Gould, Ph.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Ms. Saryah Azmat
Ms. Saryah Azmat
Chief Operating Officer, Corporate Secretary
Chief Operating Officer, Corporate Secretary
--
--
Dr. Sammy J. Farah, Ph.D.
Dr. Sammy J. Farah, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. William D. Waddill
Mr. William D. Waddill
Independent Director
Independent Director
--
--
Dr. Jerel Davis, Ph.D.
Dr. Jerel Davis, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Michael F. (Mike) Burgess, Ph.D.
Dr. Michael F. (Mike) Burgess, Ph.D.
Director
Director
--
--
Mr. Rishi Gupta, J.D.
Mr. Rishi Gupta, J.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Sun, Jul 20
Updated: Sun, Jul 20
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
OrbiMed Advisors, LLC
13.39%
Versant Ventures
11.78%
Fidelity Management & Research Company LLC
4.90%
BML Capital Management LLC
4.77%
PFM Health Sciences, LP
4.03%
Other
61.13%
Shareholders
Shareholders
Proportion
OrbiMed Advisors, LLC
13.39%
Versant Ventures
11.78%
Fidelity Management & Research Company LLC
4.90%
BML Capital Management LLC
4.77%
PFM Health Sciences, LP
4.03%
Other
61.13%
Shareholder Types
Shareholders
Proportion
Private Equity
13.39%
Investment Advisor
12.46%
Venture Capital
11.94%
Hedge Fund
8.19%
Corporation
3.87%
Research Firm
3.85%
Individual Investor
3.83%
Investment Advisor/Hedge Fund
3.45%
Other
39.02%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
91
14.11M
60.98%
-3.20M
2025Q1
90
14.01M
60.52%
-3.30M
2024Q4
88
15.36M
66.43%
+1.59M
2024Q3
85
15.71M
67.93%
+1.61M
2024Q2
83
16.98M
73.40%
+2.52M
2024Q1
68
17.94M
77.68%
+4.84M
2023Q4
62
19.03M
82.71%
+6.82M
2023Q3
53
18.21M
79.74%
+10.23M
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
OrbiMed Advisors, LLC
3.10M
13.39%
--
--
Mar 31, 2025
Versant Ventures
2.73M
11.78%
-655.37K
-19.38%
Mar 17, 2025
Fidelity Management & Research Company LLC
1.13M
4.9%
-50.06K
-4.23%
Mar 31, 2025
BML Capital Management LLC
1.10M
4.77%
+1.10M
--
Mar 31, 2025
PFM Health Sciences, LP
932.35K
4.03%
--
--
Mar 31, 2025
Takeda Pharmaceutical Co Ltd
895.82K
3.87%
--
--
Mar 31, 2025
BofA Global Research (US)
891.53K
3.85%
+5.00
+0.00%
Mar 31, 2025
Langer (Timothy J)
885.63K
3.83%
-302.18K
-25.44%
May 13, 2024
Point72 Asset Management, L.P.
878.93K
3.8%
-55.43K
-5.93%
Mar 31, 2025
72 Investment Holdings, LLC
549.98K
2.38%
--
--
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
iShares Russell 2000 ETF
0%
iShares Russell 2000 Value ETF
0%
iShares Russell 2000 Growth ETF
0%
Global X Russell 2000 ETF
0%
iShares Micro-Cap ETF
0%
ProShares Hedge Replication ETF
0%
ProShares UltraPro Russell2000
0%
Global X Russell 2000 Covered Call ETF
0%
Proshares Ultra Russell 2000
0%
iShares Russell 2000 ETF
Proportion0%
iShares Russell 2000 Value ETF
Proportion0%
iShares Russell 2000 Growth ETF
Proportion0%
Global X Russell 2000 ETF
Proportion0%
iShares Micro-Cap ETF
Proportion0%
ProShares Hedge Replication ETF
Proportion0%
ProShares UltraPro Russell2000
Proportion0%
Global X Russell 2000 Covered Call ETF
Proportion0%
Proshares Ultra Russell 2000
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
